The effects of non-prostaglandin hypotensive drops with preservative on central retinal thickness after phacoemulsification

Abstract

BACKGROUND: Primary open angle glaucoma is often associated with cataract. The correlation between the use hypotensive drops, in particular non-prostaglandin hypotensive drops with preservative, and the change in central retinal thickness after phacoemulsification with intraocular lens implantation continues to be relevant.

AIM: To evaluate central retinal thickness and pseudophakic cystoid macular edema incidence after phacoemulsification with intraocular lens implantation in patients with primary open-angle glaucoma using non-prostaglandin hypotensive drops with preservatives.

MATERIALS AND METHODS: 94 patients (108 eyes) with cataract were enrolled in the study, divided into 3 groups: the first group — 21 patients (27 eyes), and the second group — 21 patients (23 eyes) with primary open-angle glaucoma using non-prostaglandin hypotensive drops with preservative; the third (control) group included 52 patients (58 eyes) without ocular comorbidities. All patients underwent uncomplicated phacoemulsification with intraocular lens implantation. In the post-op period, patients of the first group received topical antibiotics and steroids, patients of the second and the third groups received the same treatment and non-steroidal anti-inflammatory drops as well. Central retinal thickness was measured using optical coherence tomography before surgery, 2 weeks, 2 and 6 months after surgery.

RESULTS: The central retinal thickness increase in comparison with baseline values was more significant in the first group than in the second and the third groups, and the time of recovery to baseline values during 6 months after surgery was longer. Pseudophakic cystoid macular edema was not identified in any group.

CONCLUSIONS: The use non-prostaglandin drops with preservative in patients with primary open-angle glaucoma does not affect pseudophakic cystoid macular edema development after uncomplicated phacoemulsification. Instillations of non-steroidal anti-inflammatory drops in the post-op period reduce the time of central retinal thickness recovery to baseline value.

Keywords

central retinal thickness / phacoemulsification / primary open-angle glaucoma / pseudophakic cystoid macular edema / non-steroidal anti-inflammatory drops / preservative / optical coherence tomography

References

[1] Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47(S1):S203–S218. DOI: 10.1016/s0039-6257(02)00294-1

[2] Miyake K., Ibaraki N. Prostaglandins and cystoid macular edema // Surv Ophthalmol. 2002. Vol. 47, No. S1. P. S203–S218. DOI: 10.1016/s0039-6257(02)00294-1

[3] Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105(2):263–268. DOI: 10.1016/s0161-6420(98)92977-3

[4] Warwar R.E., Bullock J.D., Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review of 94 patients // Ophthalmology. 1998. Vol. 105, No. 2. P. 263–268. DOI: 10.1016/s0161-6420(98)92977-3

[5] Lima MC, Paranhos A Jr, Salim S, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000;9(4):317–321. DOI: 10.1097/00061198-200008000-00006

[6] Lima M.C., Paranhos A. Jr., Salim S., et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost // J Glaucoma. 2000. Vol. 9, No. 4. P. 317–321. DOI: 10.1097/00061198-200008000-00006

[7] Michels RG, Maumenee AE. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes. Am J Ophthalmol. 1975;80(3):379–388. DOI: 10.1016/0002-9394(75)90522-x

[8] Michels R.G., Maumenee A.E. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes // Am J Ophthalmol. 1975. Vol. 80, No. 3. P. 379–388. DOI: 10.1016/0002-9394(75)90522-x

[9] Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol. 1968;79(5):552–562. DOI: 10.1001/archopht.1968.03850040554010

[10] Kolker A.E., Becker B. Epinephrine maculopathy // Arch Ophthalmol. 1968. Vol. 79, No. 5. P. 552–562. DOI: 10.1001/archopht.1968.03850040554010

[11] Mehelas TJ, Kollarits CR, Martin WG. Cystoid macular edema presumably induced by dipivefrin hydrochloride (Propine). Am J Ophthalmol. 1982;94(5):682. DOI: 10.1016/0002-9394(82)90019-8

[12] Mehelas T.J., Kollarits C.R., Martin W.G. Cystoid macular edema presumably induced by dipivefrin hydrochloride (Propine) // Am J Ophthalmol. 1982. Vol. 94, No. 5. P. 682. DOI: 10.1016/0002-9394(82)90019-8

[13] Hesse RJ, Swan JL. Aphakic cystoid macular edema secondary to betaxolol therapy. Ophthalmic Surg Lasers Imaging Retina. 1988;19(8):562–564. DOI: 10.3928/1542-8877-19880801-10

[14] Hesse R.J., Swan J.L. Aphakic cystoid macular edema secondary to betaxolol therapy // Ophthalmic Surg Lasers Imaging Retina. 1988. Vol. 19, No. 8. P. 562–564. DOI: 10.3928/1542-8877-19880801-10

[15] Kim P, Lertsumitkul S. Cystoid macular oedema associated with brimonidine therapy. Clin Exp Ophthalmol. 2003;31(2):165–166. DOI: 10.1046/j.1442-9071.2003.00628.x

[16] Kim P., Lertsumitkul S. Cystoid macular oedema associated with brimonidine therapy // Clin Exp Ophthalmol. 2003. Vol. 31, No. 2. P. 165–166. DOI: 10.1046/j.1442-9071.2003.00628.x

[17] Miyake K, Octa I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001;119(3):387–394. DOI: 10.1001/archopht.119.3.387

[18] Miyake K., Octa I., Ibaraki N., et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia // Arch Ophthalmol. 2001. Vol. 119, No. 3. P. 387–394. DOI: 10.1001/archopht.119.3.387

[19] Astakhov SY, Astakhov YS, Gobedzhishvili MV. The influence of prostaglandin analogs on the retinal thickness after phacoemulsification with intraocular lens implantation in primary open-angle glaucoma patients. Ophthalmology Reports. 2014;7(3):73–76. (In Russ.) DOI: 10.17816/OV2014373-76

[20] Астахов С.Ю., Астахов Ю.С., Гобеджишвили М.В. Влияние лечения аналогами простагландинов на толщину сетчатки после факоэмульсификации с имплантацией интраокулярной линзы у больных первичной открытоугольной глаукомой // Офтальмологические ведомости. 2014. Т. 7, № 3. С. 73–76. DOI: 10.17816/OV2014373-76

[21] Irvine SR. A newly defined vitreous syndrome following cataract surgery: Interpreted according to recent concepts of the structure of the vitreous. The seventh Francis I. Proctor Lecture. Am J Ophthalmol. 1953;36(5):599–619. DOI: 10.1016/0002-9394(53)90302-x

[22] Irvine S.R. A newly defined vitreous syndrome following cataract surgery: Interpreted according to recent concepts of the structure of the vitreous. The seventh Francis I. Proctor Lecture // Am J Ophthalmol. 1953. Vol. 36, No. 5. P. 599–619. DOI: 10.1016/0002-9394(53)90302-x

[23] Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557–634.

[24] Flach A.J. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery // Trans Am Ophthalmol Soc. 1998. Vol. 96. P. 557–634.

[25] Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8): 1446–1449. DOI: 10.1016/j.ophtha.2006.03.027

[26] Lardenoye C.W.T.A., van Kooij B., Rothova A. Impact of macular edema on visual acuity in uveitis // Ophthalmology. 2006. Vol. 113, No. 8. P. 1446–1449. DOI: 10.1016/j.ophtha.2006.03.027

[27] Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123(2):316–323. DOI: 10.1016/j.ophtha.2015.10.001

[28] Chu C.J., Johnston R.L., Buscombe C., et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes // Ophthalmology. 2016. Vol. 123, No. 2. P. 316–323. DOI: 10.1016/j.ophtha.2015.10.001

[29] Rotsos TG, Moschos MM. Cystoid macular edema. Clin Ophthalmol. 2008;2(4):919–930. DOI: 10.2147/opth.s4033

[30] Rotsos T.G., Moschos M.M. Cystoid macular edema // Clin Ophthalmol. 2008. Vol. 2, No. 4. P. 919–930. DOI: 10.2147/opth.s4033

[31] Kokorev VL. The analysis of risk factors of development of macular edema after phacoemulsification. Ophthalmology in Russia. 2019;16(2):185–191. (In Russ.) DOI: 10.18008/1816-5095-2019-2-185-191

[32] Кокорев В.Л. Анализ факторов риска развития макулярного отёка после факоэмульсификации катаракты // Офтальмология. 2019. Т. 16, № 2. С. 185–191. DOI: 10.18008/1816-5095-2019-2-185-191

[33] Shah N, Maguire MG, Martin DF, et al. Angiographic cystoid macular edema and outcomes in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(4):858–864. DOI: 10.1016/j.ophtha.2015.11.030

[34] Shah N., Maguire M.G., Martin D.F., et al. Angiographic cystoid macular edema and outcomes in the comparison of age-related macular degeneration treatments trials // Ophthalmology. 2016. Vol. 123, No. 4. P. 858–864. DOI: 10.1016/j.ophtha.2015.11.030

[35] Hajali M, Fishman GA, Anderson RJ. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol. 2008;92(8):1065–1068. DOI: 10.1136/bjo.2008.138560

[36] Hajali M., Fishman G.A., Anderson R.J. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography // Br J Ophthalmol. 2008. Vol. 92, No. 8. P. 1065–1068. DOI: 10.1136/bjo.2008.138560

[37] Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc. 2005;103:537–567.

[38] Johnson M.W. Perifoveal vitreous detachment and its macular complications // Trans Am Ophthalmol Soc. 2005. Vol. 103. P. 537–567.

[39] Henderson BA, Kim JY, Ament CS, et al. Clinical pseudophakic cystoid macular edema: risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33(9):1550–1558. DOI: 10.1016/j.jcrs.2007.05.013

[40] Henderson B.A., Kim J.Y., Ament C.S., et al. Clinical pseudophakic cystoid macular edema: risk factors for development and duration after treatment // J Cataract Refract Surg. 2007. Vol. 33, No. 9. P. 1550–1558. DOI: 10.1016/j.jcrs.2007.05.013

[41] Schaub F, Adler W, Enders P, et al. Preexisting epiretinal membrane is associated with pseudophakic cystoid macular edema. Graefe’s Arch Clin Exp Ophthalmol. 2018;256:909–917. DOI: 10.1007/s00417-018-3954-4

[42] Schaub F., Adler W., Enders P., et al. Preexisting epiretinal membrane is associated with pseudophakic cystoid macular edema // Graefe’s Arch Clin Exp Ophthalmol. 2018. Vol. 256. P. 909–917. DOI: 10.1007/s00417-018-3954-4

[43] Wendel C, Zakrzewski H, Carleton B, et al. Association of postoperative topical prostaglandin analog or beta-blocker use and incidence of pseudophakic cystoid macular edema. J Glaucoma. 2018;27(5):402–406. DOI: 10.1097/IJG.0000000000000929

[44] Wendel C., Zakrzewski H., Carleton B., et al. Association of postoperative topical prostaglandin analog or beta-blocker use and incidence of pseudophakic cystoid macular edema // J Glaucoma. 2018. Vol. 27, No. 5. P. 402–406. DOI: 10.1097/IJG.0000000000000929

[45] Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Int Med. 2012;172(13):1005–1011. DOI: 10.1001/archinternmed.2012.1938

[46] Idris I., Warren G., Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes // Arch Int Med. 2012. Vol. 172, No. 13. P. 1005–1011. DOI: 10.1001/archinternmed.2012.1938

[47] Yokoe T, Fukada I, Kobayashi K, et al. Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review. Case Rep Oncol. 2017;10(2):605–612. DOI: 10.1159/000477897

[48] Yokoe T., Fukada I., Kobayashi K., et al. Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review // Case Rep Oncol. 2017. Vol. 10, No. 2. P. 605–612. DOI: 10.1159/0004778972.

[49] Gass JDM. Nicotinic acid maculopathy. Am J Ophthalmol. 1973;76(4):500–510. DOI: 10.1016/0002-9394(73)90738-1

[50] Gass J.D.M. Nicotinic acid maculopathy // Am J Ophthalmol. 1973. Vol. 76, No. 4. P. 500–510. DOI: 10.1016/0002-9394(73)90738-1

[51] Millay RH, Klein ML, Illingworth DR. Niacin maculopathy. Ophthalmology. 1988;95(7):930–936. DOI: 10.1016/s0161-6420(88)33073-3

[52] Millay R.H., Klein M.L., Illingworth D.R. Niacin maculopathy // Ophthalmology. 1988. Vol. 95, No. 7. P. 930–936. DOI: 10.1016/s0161-6420(88)33073-3

[53] Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol. 1995;79(1):54–56. DOI: 10.1136/bjo.79.1.54

[54] Fraunfelder F.W., Fraunfelder F.T., Illingworth D.R. Adverse ocular effects associated with niacin therapy // Br J Ophthalmol. 1995. Vol. 79, No. 1. P. 54–56. DOI: 10.1136/bjo.79.1.54

[55] Callanan D, Blodi BA, Martin DF. Macular edema associated with nicotinic acid (niacin). JAMA. 1998;279(21):1702–1702. DOI: 10.1001/jama.279.21.1702-b

[56] Callanan D., Blodi B.A., Martin D.F. Macular edema associated with nicotinic acid (niacin) // JAMA. 1998. Vol. 279, No. 21. P. 1702–1702. DOI: 10.1001/jama.279.21.1702-b

[57] Domanico D, Verboschi F, Altimari S, et al. Ocular effects of niacin: a review of the literature. Med Hypothesis Discov Innov Ophthalmol. 2015;4(2):64–71.

[58] Domanico D., Verboschi F., Altimari S., et al. Ocular effects of niacin: a review of the literature // Med Hypothesis Discov Innov Ophthalmol. 2015. Vol. 4, No. 2. P. 64–71.

[59] Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78(9):672–680. DOI: 10.1212/WNL.0b013e318248deea

[60] Jain N., Bhatti M.T. Fingolimod-associated macular edema: incidence, detection, and management // Neurology. 2012. Vol. 78, No. 9. P. 672–680. DOI: 10.1212/WNL.0b013e318248deea

[61] Lee KM, Lee EJ, Kim T-W, Kim H. Pseudophakic macular edema in primary open-angle glaucoma: a prospective study using spectral-domain optical coherence tomography. Am J Ophthalmol. 2017;179:97–109. DOI: 10.1016/j.ajo.2017.05.001

[62] Lee K.M., Lee E.J., Kim T.-W., Kim H. Pseudophakic macular edema in primary open-angle glaucoma: a prospective study using spectral-domain optical coherence tomography // Am J Ophthalmol. 2017. Vol. 179. P. 97–109. DOI: 10.1016/j.ajo.2017.05.001

[63] Williams DE, Nguyen KD, Shapourifar-Tehrani S, et al. Effects of timolol, betaxolol, and levobunolol on human tenon’s fibroblasts in tissue culture. Investig Ophthalmol Vis Sci. 1992;33(7):2233–2241.

[64] Williams D.E., Nguyen K.D., Shapourifar-Tehrani S., et al. Effects of timolol, betaxolol, and levobunolol on human tenon’s fibroblasts in tissue culture // Investig Ophthalmol Vis Sci. 1992. Vol. 33, No. 7. P. 2233–2241.

[65] Baudouin C, Pisella P-J, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106(3):556–563. DOI: 10.1016/S0161-6420(99)90116-1

[66] Baudouin C., Pisella P.-J., Fillacier K., et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies // Ophthalmology. 1999. Vol. 106, No. 3. P. 556–563. DOI: 10.1016/S0161-6420(99)90116-1

[67] Miyake K, Ibaraki N, Goto Y, et al. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003;29(9):1800–1810. DOI: 10.1016/s0886-3350(03)00560-1

[68] Miyake K., Ibaraki N., Goto Y., et al. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy // J Cataract Refract Surg. 2003. Vol. 29, No. 9. P. 1800–1810. DOI: 10.1016/s0886-3350(03)00560-1

[69] Sánchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, et al. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci. 2002;43(5):1588–1594.

[70] Sánchez-Tocino H., Alvarez-Vidal A., Maldonado M.J., et al. Retinal thickness study with optical coherence tomography in patients with diabetes // Invest Ophthalmol Vis Sci. 2002. Vol. 43, No. 5. P. 1588–1594.

[71] von Jagow B, Ohrloff C, Kohnen T. Macular thickness after uneventful cataract surgery determined by optical coherence tomography. Graefe’s Arch Clin Exp Ophthalmol. 2007;245:1765–1771. DOI: 10.1007/s00417-007-0605-6

[72] von Jagow B., Ohrloff C., Kohnen T. Macular thickness after uneventful cataract surgery determined by optical coherence tomography // Graefe’s Arch Clin Exp Ophthalmol. 2007. Vol. 245. P. 1765–1771. DOI: 10.1007/s00417-007-0605-6

[73] Perente I, Utine CA, Ozturker C, et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr Eye Res. 2007;32(3):241–247. DOI: 10.1080/02713680601160610

[74] Perente I., Utine C.A., Ozturker C., et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography // Curr Eye Res. 2007. Vol. 32, No. 3. P. 241–247. DOI: 10.1080/02713680601160610

[75] Ching H-Y, Wong AC, Wong C-C, et al. Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography. Eye. 2006;20(3):297–303. DOI: 10.1038/sj.eye.6701864

[76] Ching H.-Y., Wong A.C., Wong C.-C., et al. Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography // Eye. 2006. Vol. 20, No. 3. P. 297–303. DOI: 10.1038/sj.eye.6701864

[77] Wang X, Astakhov SY, Potemkin VV, et al. Evaluation of retinal thickness and of pseudophakic cystoid macular edema incidence in patients with primary open-angle glaucoma treated with prostaglandin analogues. Ophthalmology Reports. 2021;14(2):17–26. (In Russ.) DOI: 10.17816/OV64116

[78] Ван С., Астахов С.Ю., Потемкин В.В., и др. Оценка толщины сетчатки и частоты развития псевдофакичного кистозного макулярного отёка у больных ПОУГ, получающих аналоги простагландинов // Офтальмологические ведомости. 2021. Т. 14, № 2. C. 17–26. DOI: 10.17816/OV64116

[79] Kurt A, Kılıç R. The effects of uncomplicated cataract surgery on retinal layer thickness. J Ophthalmol. 2018;2018:7218639. DOI: 10.1155/2018/7218639

[80] Kurt A., Kılıç R. The effects of uncomplicated cataract surgery on retinal layer thickness // J Ophthalmol. 2018. Vol. 2018. ID7218639. DOI: 10.1155/2018/7218639

[81] Cagini C, Fiore T, Laccheri B, et al. Macular thickness measured by optical coherence tomography in a healthy population before and after uncomplicated cataract phacoemulsification surgery. Curr Eye Res. 2009;34(12):1036–1041. DOI: 10.3109/02713680903288937

[82] Cagini C., Fiore T., Laccheri B., et al. Macular thickness measured by optical coherence tomography in a healthy population before and after uncomplicated cataract phacoemulsification surgery // Curr Eye Res. 2009. Vol. 34, No. 12. P. 1036–1041. DOI: 10.3109/02713680903288937

[83] Falcão MS, Gonçalves N, Freitas-Costa P, et al. Choroidal and macular thickness changes induced by cataract surgery. Clin Ophthalmol. 2013;8:55–60. DOI: 10.2147/OPTH.S53989

[84] Falcão M.S., Gonçalves N., Freitas-Costa P., et al. Choroidal and macular thickness changes induced by cataract surgery // Clin Ophthalmol. 2013. Vol. 8. P. 55–60. DOI: 10.2147/OPTH.S53989

RIGHTS & PERMISSIONS

Eco-Vector